Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cardiac Fibrosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cardiac Fibrosis - Pipeline Review, H2 2014', provides an overview of the Cardiac Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cardiac Fibrosis Overview 6 Therapeutics Development 7 Pipeline Products for Cardiac Fibrosis - Overview 7 Pipeline Products for Cardiac Fibrosis - Comparative Analysis 8 Cardiac Fibrosis - Therapeutics under Development by Companies 9 Cardiac Fibrosis - Therapeutics under Investigation by Universities/Institutes 10 Cardiac Fibrosis - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Cardiac Fibrosis - Products under Development by Companies 13 Cardiac Fibrosis - Products under Investigation by Universities/Institutes 14 Cardiac Fibrosis - Companies Involved in Therapeutics Development 15 Daiichi Sankyo Company, Limited 15 BioLineRx, Ltd. 16 Galectin Therapeutics, Inc. 17 Digna Biotech, S.L. 18 Promedior, Inc. 19 miRagen Therapeutics, Inc. 20 Cardiac Fibrosis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 CARD-024 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 SP-20102 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 P-17 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 disitertide - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CGEN-856 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 GM-CT-01 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 PRM-151 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MGN-4220 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 GR-MD-02 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 PN1-Ab - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 TM-5441 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Cardiac Fibrosis - Recent Pipeline Updates 49 Cardiac Fibrosis - Dormant Projects 60 Cardiac Fibrosis - Product Development Milestones 61 Featured News & Press Releases 61 Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
List of Tables Number of Products under Development for Cardiac Fibrosis, H2 2014 7 Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Cardiac Fibrosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 15 Cardiac Fibrosis - Pipeline by BioLineRx, Ltd., H2 2014 16 Cardiac Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 17 Cardiac Fibrosis - Pipeline by Digna Biotech, S.L., H2 2014 18 Cardiac Fibrosis - Pipeline by Promedior, Inc., H2 2014 19 Cardiac Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Cardiac Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 49 Cardiac Fibrosis - Dormant Projects, H2 2014 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.